Aminoalcohol lipidoids and uses thereof
Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.
1. A compound of formula:
wherein:
A is substituted or unsubstituted, branched or unbranched, cyclic or acyclic, C 2-20 alkylene, optionally interrupted by 1 or more heteroatoms independently selected from the group consisting of O, S, and N, or A is a substituted or unsubstituted, saturated or unsaturated, 4-6-membered ring;
one occurrence of R 1 is substituted or unsubstituted, branched or unbranched, C 1-20 -aliphatic, or substituted or unsubstituted, branched or unbranched, C 1-20 heteroaliphatic, and the other occurrence of R 1 is hydrogen;
one occurrence of R 2 is substituted or unsubstituted, branched or unbranched, C 1-20 -aliphatic, or substituted or unsubstituted, branched or unbranched, C 1-20 heteroaliphatic, and the other occurrence of R 2 is hydrogen;
one occurrence of R 3 is substituted or unsubstituted, branched or unbranched, C 1-20 -aliphatic, or substituted or unsubstituted, branched or unbranched, C 1-20 heteroaliphatic, and the other occurrence of R 3 is hydrogen;
R B , R C , and R D are, independently, hydrogen, substituted or unsubstituted, branched or unbranched, C 1-20 -aliphatic, substituted or unsubstituted, branched or unbranched, C 1-20 -heteroaliphatic, or —CH 2 CH(OH)R E ;
or R C and R D together form a cyclic structure;
or R B and R D together form a cyclic structure; and
R E is substituted or unsubstituted, branched or unbranched, C 1-20 aliphatic, or substituted or unsubstituted, branched or unbranched, C 1-20 heteroaliphatic;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein
3. The compound of claim 1 , wherein
4. The compound of claim 1 , wherein each of R B , R C , and R D is independently hydrogen, or substituted or unsubstituted, C 1 -C 6 alkyl.
5. The compound of claim 1 , wherein each of R B , R C , and R D is hydrogen.
6. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently:
7. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched, C 1 -C 20 aliphatic.
8. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently, unsubstituted, acyclic, branched or unbranched, C 1 -C 20 aliphatic.
9. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are fluorinated C 1 -C 20 aliphatic.
10. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched, C 1 -C 20 alkyl.
11. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently:
12. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently, substituted or unsubstituted, cyclic or acyclic, branched or unbranched, C 2 -C 20 alkenyl.
13. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently:
14. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently:
15. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently:
16. The compound of claim 1 , wherein one occurrence of R 1 , one occurrence of R 2 , and one occurrence of R 3 are, independently, unsubstituted, acyclic, branched or unbranched, C 1 -C 20 heteroaliphatic.
17. The compound of claim 1 , wherein A is substituted or unsubstituted, branched or unbranched, cyclic or acyclic, C 2-20 alkylene.
18. The compound of claim 1 , wherein A is substituted or unsubstituted, branched or unbranched, cyclic or acyclic, C 2-20 alkylene interrupted by 1 or more heteroatoms independently selected from the group consisting of O, S, and N.
19. The compound of claim 1 , wherein A is:
20. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
21. A pharmaceutical composition comprising:
a compound of claim 1 , or a pharmaceutically acceptable salt thereof; and
a pharmaceutical agent.
22. A method of delivering an agent, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:
a compound of claim 1 , or a pharmaceutically acceptable salt thereof; and
an agent to be delivered.
23. The pharmaceutical composition of claim 21 , wherein the pharmaceutical agent is selected from the groups consisting of polynucleotides, proteins, peptides, and small molecule drugs.
24. The pharmaceutical composition of claim 21 , wherein the pharmaceutical agent is a polynucleotide.
25. The pharmaceutical composition of claim 21 , wherein the polynucleotide is DNA.
26. The pharmaceutical composition of claim 21 , wherein the polynucleotide is RNA.
27. The pharmaceutical composition of claim 26 , wherein the RNA is dsRNA, siRNA, shRNA, miRNA, or antisense RNA.
28. The pharmaceutical composition of claim 24 , wherein the polynucleotide encodes a protein or peptide.
29. The pharmaceutical composition of claim 21 , wherein the pharmaceutical agent is a protein.
30. The pharmaceutical composition of claim 21 , wherein the pharmaceutical agent is a peptide.
31. The pharmaceutical composition of claim 21 , wherein the pharmaceutical agent is a small molecule drug.
32. The method of claim 22 , wherein the agent is selected from the groups consisting of polynucleotides, proteins, peptides, and small molecule drugs.
33. The method of claim 32 , wherein the agent is a polynucleotide.
34. The method of claim 33 , wherein the polynucleotide is DNA.
35. The method of claim 33 , wherein the polynucleotide is RNA.
36. The method of claim 35 , wherein the RNA is dsRNA, siRNA, shRNA, miRNA, or antisense RNA.
37. The method of claim 33 , wherein the polynucleotide encodes a protein or peptide.
38. The method of claim 21 , wherein the agent is a protein.
39. The method of claim 21 , wherein the agent is a peptide.
40. The method of claim 21 , wherein the agent is a small molecule drug.